Owning Commonwealth Bank of Australia (ASX: CBA) shares typically means receiving a good dividend each year. But, the size of the dividend over the next few years could be influential for investors who are deciding whether to make an investment.

CBA is still capable of producing loan growth and profit growth. However, it’s now a huge bank, so future growth may not be as compelling as the last 10 to 15 years. With that in mind, the dividends could play an important role in its appeal and overall returns for Australians.

Let’s look at the forecasts of where experts think the dividends for owners of CBA shares could go over the next few years.

First, FY26

The 2026 financial year is the one we’re currently in and is just over halfway. In February, we’ll learn how much profit CBA made in the six months to December 2025 and the size of the interim dividend.

For the annual FY26 result, the projection on CMC Markets suggests that the ASX bank share‘s earnings per share (EPS) could rise slightly and this could fund a 2% hike of the dividend payout to $4.95 per CBA share.

This projection translates into a potential grossed-up dividend yield of 4.6%, including the franking credits.

Then, FY27

In the next financial year, the estimate on CMC Markets suggests that net profit could increase at a pace that’s a little faster.

Pleasingly, stronger profit growth is expected to translate into a bigger dividend increase. In the 2027 financial year, the expert projection suggests the bank could deliver a 3% rise in its payout to $5.10 per share.

At the time of writing, the projected potential payout would equate to a grossed-up dividend yield of 4.75%, including franking credits.

Finally, FY28

Steady progression is expected to continue for owners of CBA shares in FY28.

While rapid growth isn’t forecast, that may not be what investors are looking for from the ASX bank share. Steady and dependable may be what some Australian investors are after.

The profit projection on CMC Markets suggests EPS could rise approximately 5% to $6.73. This could pay for a measly 1% rise in the payout to $5.155 per share. This forecast dividend would translate into a grossed-up dividend yield of 4.8%, including franking credits.

Is the CBA share price a buy?

All nine of the recent analyst recommendations on the ASX bank share are a sell, according to CMC Markets. There is consensus among experts that CBA shares are overvalued, with an average price target suggesting it could fall by more than 20% over the next year. While existing shareholders don’t have to sell, it could be wise to invest new money in other available opportunities.

The post Here’s the dividend forecast out to 2028 for CBA shares appeared first on The Motley Fool Australia.

More reading

• With inflation edging lower, here’s the latest 2026 interest rate forecast from CBA
• Why Bellevue Gold, Harvey Norman, Karoon Energy, and Westpac shares are falling today
• Australian Bank Stocks: Which ones look like a buy (and which don’t)
• Why CBA is forecasting a stronger Aussie dollar in 2026, and what that means if you’re buying ASX shares
• Why Andean Silver, CBA, Life360, and Silex shares are dropping today

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

S&P/ASX 200 Index (ASX: XJO) healthcare stock Ansell Limited (ASX: ANN) is taking a tumble today.

Shares in the health and safety products company closed yesterday trading for $35.58. In morning trade on Thursday, shares are swapping hands for $34 apiece, down 4%. That gives Ansell a market cap of just under $4.9 billion.

For some context, the ASX 200 is up 0.1% at this same time.

Today’s underperformance of Anell shares looks to be driven by news of a top leadership changeover.

Here’s what’s happening.

ASX 200 healthcare stock under new leadership

Before market open today, Ansell announced that Neil Salmon has decided to retire from his role as managing director and CEO.

Salmon has been with the company for 13 years and has served as CEO since 2021.

The ASX 200 healthcare stock reported that Nathalie Ahlstrom will succeed Salmon as CEO and managing director. She will join Ansell on 26 January for a transition period, before taking over the reins on 16 February.

Salmon will then continue as a special advisor to the board and to Ahlstrom until 30 June, helping to provide a smooth transition.

The Ansell board noted that Ahlstrom brings strong global experience. Until recently, she served as CEO and president of the Fiskars Group, with the board expressing confidence that she is the right leader to steer Ansell through its “next chapter of innovation and growth”.

Ahlstrom will be based out of Ansell’s Brussels hub in Belgium.

What did management say?

Commenting on the CEO transition that’s throwing up headwinds for the ASX 200 healthcare stock today, Ansell chair Nigel Garrard said, “We are delighted to appoint Nathalie as Ansell’s next managing director and CEO.”

Garrard continued:

Nathalie brings exceptional leadership experience, a track record of delivering results in complex global markets, and a deep understanding of innovation and operational excellence. These qualities, combined with her strategic vision, will help ensure that Ansell continues to strengthen its market position and deliver long-term value for our stakeholders.

Addressing the outgoing CEO, Garrard said, “Neil has played a pivotal role over his 13 years with Ansell and, as CEO, in creating the foundations of the company’s recent success.”

Garrard added, “Results can be seen in strong organic growth in difficult market conditions, improved productivity and success implementing the company’s long term sustainability strategy.”

“Ansell is a wonderful organisation to lead,” outgoing CEO Salmon said.

Salmon concluded:

It has been very rewarding to see the company flourish and deliver on our ambitious goals during my time as CEO…

As I prepare to conclude my executive career, I look forward to supporting a smooth transition and to assist Nathalie in any way I can.

With today’s intraday fall in the Ansell share price factored in, shares in the ASX 200 healthcare stock are up 0.8% over 12 months, and up 11.5% over the past six months.

The post $5 billion ASX 200 healthcare stock tumbling on CEO exit appeared first on The Motley Fool Australia.

More reading

• Ansell announces CEO transition: Nathalie Ahlström to succeed Neil Salmon in 2026
• Analysts name 2 top ASX 200 shares to buy today

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Ansell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Ramelius Resources Ltd (ASX: RMS) shares are on the slide on Thursday morning.

At the time of writing, the ASX 200 gold stock is down 3% to $4.12.

Why is this ASX 200 gold stock dropping?

Investors have been selling the gold miner’s shares for a couple of reasons.

One is a pullback in the gold price, which is putting pressure on most ASX 200 gold stocks today.

The other reason is the release of Ramelius’ quarterly update.

What did it announce?

For the three months ended 31 December, the company achieved gold production of 45,610 ounces. This was down 17% from 55,013 ounces in the previous quarter.

This means that year to date gold production is now 100,623 ounces. Management believes this leaves it positioned to meet its FY 2026 guidance of 185,000 ounces to 205,000 ounces.

The ASX 200 gold stock also revealed that it delivered underlying free cash flow of $67 million for the three months, which is down from $129 million in the first quarter. This was before an FY 2025 income tax payment of $118.2 million and a return of $60.3 million through dividend payments to shareholders.

At the end of the period, its cash and gold balance of $694.3 million.

What else?

Outside this, the company provided an update on its developments.

It advised that the Dalgaranga mine development remains on time and on budget with first Never Never ore targeted to be delivered to the Mt Magnet hub in the March 2026 quarter.

In addition, Mt Magnet plant expansion activities were focused on plant engineering works, preliminary site works and establishment of the execution team.

A significant milestone was achieved on the Rebecca-Roe project with the signing of the Native Title Mining Agreement with Kakarra Part B Native Title Holders.

Commenting on its performance, the ASX 200 gold stock’s chief operating officer, Tim Hewitt, said:

We continue to build on the strong momentum from our first quarter and remain on track to deliver our FY26 guidance with production year-to-date of 100,623 ounces. Mt Magnet produced 45,610 ounces in the quarter, in line with our plan with strong contribution from Penny and Cue mines.

Importantly, the development of the Dalgaranga mine is on time and on budget with first ore from Never Never to be delivered to the Mt Magnet processing plant in the March 2026 quarter. We look forward to sharing an update from the recently accelerated drilling program at priority targets within our exploration portfolio in coming weeks demonstrating the significant potential upside at the Mt Magnet production hub.

The post Why is this popular ASX 200 gold stock tumbling today? appeared first on The Motley Fool Australia.

More reading

• Ramelius Resources reports steady gold output; FY26 guidance reaffirmed
• 5 things to watch on the ASX 200 on Tuesday
• Which ASX gold stock should you buy in 2026?
• Watch this ugly duckling ASX 200 gold stock in 2026
• What on earth is going on with ASX 200 gold stocks like Northern Star today?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Alcidion Group Ltd (ASX: ALC) are more than 20% higher after the company said it had been selected as the preferred supplier for a UK hospital group.

The technology company said University Hospitals Sussex NHS Foundation Trust (UHSx) had selected Alcidion as its preferred supplier for its new electronic patient record system.

The company said UHSx was a substantial healthcare provider in the UK.

UHSx is located in the south of the UK and forms part of the Sussex Integrated Care System (ICS). They provide hospital and community health care for approximately a million people in Sussex. It is one of the largest acute trusts in the UK, with seven hospitals hosting more than 1.5 million outpatient appointments, A&E visits and surgery cases annually, employing nearly 20,000 staff.

Alcidion said it would deploy its flagship Miya Precision platform, “including Miya Observations and Assessments (Patientrack), which is already live at the Trust”.

The company went on to say:

The EPR solution will provide clinicians real-time access to patient records whilst streamlining patient flow and improving clinical decision making processes. Following a competitive tender process, we will now finalise the contract prior to commencing deployment of Miya Precision which is expected to commence in Q4 FY26.

ASX technology share gaining momentum 

Alcidion Managing Director Kate Quirke said the company was “excited” to provide the expanded platform to UHSx.

This builds on a long-standing relationship Alcidion have with UHSx where they have been using Miya Observations and Assessments (Patientrack) for many years. UHSx’s purpose for the EPR procurement is to implement a single, integrated digital platform that improves patient care, supports regional integration, drives operational efficiency, and delivers long-term social and research benefits. Miya Precision is ideally placed to deliver on this vision working alongside the implementation teams and clinical staff at UHSx to ensure there is long term benefit to the people of this region.

Alcidion shares traded as high as 12 cents on the news, up 20.2% before settling back to be 11.1% higher at 11 cents.

The contract win follows another in November, involving a contract expansion with Leidos Australia to further expand its use of Miya Precision.

That contract is worth $12.3 million out to 2028, adding $2.5 million to the company’s annual recurring revenue. The company is expecting to recognise $5.5 to $6.5 million of the new revenue in FY26.

Alcidion was valued at $132.9 million at the close of trade on Wednesday.

The post This ASX technology company’s shares are surging more than 20% on a new contract win appeared first on The Motley Fool Australia.

More reading

• $5 billion ASX 200 healthcare stock tumbling on CEO exit
• Why is this popular ASX 200 gold stock tumbling today?
• This ASX tech stock is in focus after fresh US news
• The ASX 200 stocks I’d be happy to hold until retirement
• Guess which ASX All Ords stock is rocketing today on AUKUS partnership development news

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Alcidion Group. The Motley Fool Australia has recommended Alcidion Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Elsight Ltd (ASX: ELS) are in the spotlight today after the company released an update to the market.

At the time of writing, the ASX drone technology stock is down 0.83% to $3.55, after touching a record high yesterday. In comparison, the S&P/ASX All Ordinaries Index (ASX: XAO) is up 0.1%.

Despite the pullback, the recent run in Elsight shares has been very strong, including a sharp rally over the past month.

So, what did the company announce?

A meaningful US order

According to the release, Elsight revealed it has secured a US$460,000 purchase order from a US public safety customer.

This is an important step for the company because it is the first commercial order announced for 2026. It also shows that customers outside the defence sector are now buying its technology.

The order relates to drones that can fly beyond the operator’s line of sight, which allows them to cover much larger areas. This type of operation is becoming increasingly useful for emergency services, search and rescue, and monitoring large infrastructure.

Why this matters for the future

At the moment, many drone flights in the US are restricted by regulation. However, the US aviation regulator is in the process of updating its rules to allow more routine long-distance drone flights.

Elsight said these changes are moving forward and could be finalised next year. Clearer rules would make it easier for organisations to use drones more widely and with greater confidence.

When that happens, demand for reliable communication systems that keep drones connected at all times is expected to increase.

What does Elsight actually sell?

Elsight’s core product is called Halo. It keeps drones connected by using several networks at once to create a more reliable signal.

This is especially important for drones used in emergency situations, where losing connection is not an option. That makes Elsight’s technology attractive for public safety and other critical services.

The company believes public safety could be one of the first big commercial markets to adopt long-distance drone flights.

What the market is signalling

With shares up almost 1,000% over the past year, expectations are clearly much higher.

Today’s order adds to signs that Elsight’s technology is moving beyond trials and into real customer use. The market appears to be responding to steady progress toward regular commercial sales.

For me, this ASX defence stock remains firmly on the watchlist, along with Electro Optic Systems Holdings Ltd (ASX: EOS).

The post This ASX tech stock is in focus after fresh US news appeared first on The Motley Fool Australia.

More reading

• Why 4DMedical, Elsight, Judo, and Nickel Industries shares are pushing higher today
• ASX drone stock jumps 9% to record high on US news
• Why did these ASX shares outperform their peers in 2025?
• If you think drones are the future of defence, these three ASX stocks might be for you
• This 10-bagger drone technology company has just won a lucrative new defence contract

Motley Fool contributor Aaron Teboneras has positions in Electro Optic Systems. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Electro Optic Systems. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

When investing with retirement in mind, the goal is to own businesses that can remain relevant, profitable, and resilient over many years.

The types of companies that suit this approach tend to share a few traits. They operate in markets with long-term demand, they reinvest to stay ahead of competitors, and they have business models that can adapt as technology and customer needs evolve.

With that in mind, here are three ASX 200 stocks I would be comfortable holding through market cycles and all the way through to retirement.

Cochlear Ltd (ASX: COH)

Cochlear is one of the most respected healthcare shares listed on the Australian stock exchange.

It is the world leader in implantable hearing solutions, operating in a market supported by powerful demographic tailwinds. As populations age and access to healthcare improves globally, demand for hearing implants is expected to grow steadily over time.

What makes Cochlear particularly attractive for long-term investors is its competitive position. The company benefits from deep intellectual property, strong clinician relationships, and very high switching costs. Once a patient enters the Cochlear ecosystem, they often remain within it for life, supporting recurring revenue through upgrades and accessories.

This combination of essential healthcare, innovation, and long-term customer relationships makes Cochlear a classic buy and hold candidate.

Megaport Ltd (ASX: MP1)

Another ASX 200 stock I would be happy to hold until retirement is Megaport.

It is a very different type of retirement-style investment, but its long-term potential is compelling.

The company operates a global network-as-a-service platform, which allows businesses to connect quickly and securely to cloud providers and data centres. As more workloads move to the cloud and hybrid IT environments become the norm, demand for flexible, on-demand connectivity continues to grow.

Megaport’s business model is highly scalable. Once its network infrastructure is in place, incremental customers can be added at relatively low cost, creating the potential for strong operating leverage as revenue grows. It also recently completed the acquisition of Latitude, which has increased its total addressable market materially. This bodes well for its long-term growth outlook.

ResMed Inc. (ASX: RMD)

Lastly, I think ResMed would be a great long term pick. It combines defensive healthcare characteristics with genuine growth optionality.

ResMed is a global leader in sleep apnoea and respiratory care devices, operating in a market that remains significantly underdiagnosed. In fact, the sleep apnoea treatment market is estimated to be over 1 billion sufferers.

Beyond hardware, ResMed has been expanding its software and digital health offerings, building deeper relationships with patients and healthcare providers. This shift toward connected devices and data-driven care adds a layer of recurring revenue and enhances the durability of the business.

In light of this, I think this ASX 200 stock could be a great buy and hold option for Aussie investors.

The post The ASX 200 stocks I’d be happy to hold until retirement appeared first on The Motley Fool Australia.

More reading

• How I’d build a $1,000-a-month passive income from ASX shares
• Top brokers name 3 ASX shares to buy today
• 5 incredible ASX growth stocks to buy for 2026
• This might be the most underrated artificial intelligence ASX stock to own in 2026
• How to turn small ASX share investments into life-changing money

Motley Fool contributor James Mickleboro has positions in Cochlear, Megaport, and ResMed. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear, Megaport, and ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The All Ordinaries Index (ASX: XAO) is up 0.1% in morning trade on Thursday, with ASX All Ords stock Duratec Ltd (ASX: DUR) racing ahead of those gains.

Shares in the engineering, construction, and remediation contractor closed yesterday trading for $1.865. At the time of writing, shares are changing hands for $2.030 apiece, up 8.9%.

This outperformance follows an update on the Duratec Ertech Joint Venture (DEJV), Duratec’s 50:50 joint venture with Ertech.

Here’s what’s piquing ASX investor interest.

ASX All Ords stock lifts off on contract news

Duratec shares are leaping higher after the company reported DEJV has been instructed to proceed with early procurement of some $5 million worth of long lead items.

These items will assist the program and project timing as part of the Early Contractor Involvement (ECI) for the planning phase of infrastructure upgrades to support future submarine capability at the HMAS Stirling naval base, located in Western Australia.

The ASX All Ords stock noted that additional early on-site contract works could occur as the contract design nears 100% completion and design approval is granted.

Duratec expects the award and commencement of the project in the third quarter of FY 2026.

The company said that it now expects the second contract award for the delivery of the “fit-for-purpose, nuclear regulatory compliant facilities” in the fourth quarter of FY 2026. This will help support the expansion and enhancement requirements of the Department of Defence’s infrastructure upgrade at HMAS Stirling. The ASX All Ords stock added that there is the potential to undertake early works via the current planning phase contract.

The infrastructure upgrades and projects are being carried out ahead of the expected arrival of the rotational force from the United States and the United Kingdom under the AUKUS partnership. Those forces are anticipated to arrive in late calendar year 2027.

What did management say?

Commenting on the early procurement news that’s sending the ASX All Ords stock flying higher today, Duratec managing director Chris Oates said, “Duratec is proud to play a key role in supporting Australia’s future submarine capability through these critical infrastructure upgrades at HMAS Stirling.”

Oates added:

The early procurement of long lead items is strong validation of Duratec’s critical involvement at HMAS Stirling and its broader partnership with the Department of Defence. We look forward to continuing our long-standing relationship with Defence to ensure the timely and compliant delivery of these strategically important facilities.

With today’s intraday boost factored in, the Duratec share price is up more than 49% since this time last year.

The post Guess which ASX All Ords stock is rocketing today on AUKUS partnership development news appeared first on The Motley Fool Australia.

More reading

• Bell Potter names three engineering companies to buy

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shares in Monadelphous Group Ltd (ASX: MND) are trading sharply higher at new record levels after the company announced $110 million worth of new contracts.

The wins follow a $175 million contract win with BHP Group Ltd (ASX: BHP) announced earlier in the week, which in turn followed a $250 million contract win with Rio Tinto Ltd (ASX: RIO) in December.

Diversified contracts won

The company said on Thursday that the new contracts were “in the resources and energy, and renewable energy sectors”.

Monadelphous said in its statement to the ASX:

The company has secured a four-year contract with BW Offshore Australia Management to provide multidisciplinary maintenance services at the BW Opal Floating Production Storage and Offloading (FPSO) facility located approximately 300 kilometres north-northwest of Darwin, Northern Territory. Work is expected to commence on the facility in the first quarter of 2026.

The company was also awarded a contract with Rio Tinto for modification works at the Hope Downs 2 iron ore project in the Pilbara region of Western Australia, with that work expected to be completed in the second half of 2026.

The company went on to say:

In Papua New Guinea, the company has secured a contract with Santos for the demolition and disposal of the Hegigio Pipeline Bridge, a 500-metre-long suspended wire bridge, located in the Southern Highlands region. Work is expected to be completed in the second half of 2026. Finally, Zenviron, the company’s renewable energy joint venture, has secured a contract with Flow Power for the delivery of the 100/223 MWh Bennetts Creek Battery Energy Storage System in the Latrobe Valley, Victoria. The work, which includes balance-of-plant design, construction, installation and commissioning, is expected to be completed in late 2027.

Strong momentum

At the company’s AGM in late November, chair Rob Velletri said the company had in 2025, secured about $2.3 billion in new contracts and contract extensions, which was a record, plus had added another $570 million since the end of the financial year.

Mr Bebic said at the time the company was forecasting revenue for the half-year ending December 30 of about $1.5 billion, with full-year revenue expected to be about 20% to 25% higher than the previous year.

Shares in Monadelphous Group have more than doubled over the past year, and were changing hands for $28.87 on Thursday morning, up 7.6%. The shares traded as high as $28.89, which was a new record, before settling back.

The shares have increased from lows of $13.36 over the past year. The company was valued at $2.68 billion at the close of trade on Monday.

The post This ASX 200 company’s shares have hit a new record high on more contract success appeared first on The Motley Fool Australia.

More reading

• Monadelphous lands $110m in new contracts across sectors
• 5 best ASX 200 industrial shares of 2025
• Why BlueScope, DroneShield, Monadelphous, and SGH shares are racing higher today
• This ASX 200 company is celebrating its second major contract win in as many months
• Monadelphous awarded $175 million BHP contract: Key details for investors

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended BHP Group. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

BlueScope Steel Ltd (ASX: BSL) shares are under pressure on Thursday morning.

At the time of writing, the steel products manufacturer’s shares are down 1% to $29.56.

What’s going on with BlueScope shares?

Investors have been hitting the sell button today after the company released an update on the takeover approach it received from a consortium comprising SGH Ltd (ASX: SGH) and Steel Dynamics, Inc (NASDAQ: STLD).

The takeover proposal offered to acquire all BlueScope shares by way of a scheme of arrangement at a price of $30.00 cash per share.

According to the release, the BlueScope board has unanimously rejected the unsolicited, non-binding, indicative, and conditional takeover proposal from the consortium.

It notes that the takeover proposal was subject to numerous conditions, including the consortium undertaking extensive due diligence on the company on an exclusive basis and securing significant debt financing.

The board unanimously rejected the takeover proposal on the basis that it “very significantly undervalued BlueScope.”

Commenting on the decision, the company’s chair, Jane McAloon, didn’t hold back. She said:

Let me be clear – this proposal was an attempt to take BlueScope from its shareholders on the cheap. It drastically undervalued our world-class assets, our growth momentum, and our future – and the Board will not let that happen. This is the fourth time we’ve said no, and the answer remained the same – BlueScope is worth considerably more than what was on the table.

The BlueScope team is well recognised for driving and delivering value for our shareholders and customers. Since its restructure was completed in financial year 2017, BlueScope has invested over $3.7 billion in growth projects, delivered over $3.8 billion of shareholder returns and achieved an 18% average return on invested capital. Under the experienced leadership of the incoming MD&CEO, Tania Archibald, the Board is highly confident that management will continue to deliver superior shareholder value.

Undervaluing its assets

BlueScope believes the consortium’s takeover proposal failed to adequately recognise the value of its assets and comes at a time of lower steel spreads in Asia.

It highlights that if steel spreads and foreign exchange rates reverted to historical average levels, this would be expected to generate an additional $400 million to $900 million of EBIT per annum relative to FY 2025.

The company also points out that the consortium are seeking to debt-fund the takeover, and BlueScope had virtually no net debt at FY 2025. As a result, it feels that the bidders are seeking to use BlueScope’s strong balance sheet to help fund their opportunistic takeover proposal.

The post BlueScope shares fall after rejecting ‘significantly undervalued’ takeover offer appeared first on The Motley Fool Australia.

More reading

• 5 things to watch on the ASX 200 on Thursday
• What’s Bell Potter’s view on SGH shares after the BlueScope Steel acquisition proposal?
• BlueScope Steel shares soar 23%: Buy, hold or sell for 2026?
• Here are the top 10 ASX 200 shares today
• Why BlueScope, DroneShield, Monadelphous, and SGH shares are racing higher today

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended Steel Dynamics. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

Shareholders in AMP Ltd (ASX: AMP) don’t have too long to wait to get some visibility over the company’s full-year results, with the company set to report to shareholders on February 12.

The company said in a statement to the ASX this week that it will report its results next month, followed by its annual general meeting on April 10.

The company’s half-year results will be announced on August 6.

Impact of legal settlements in focus

Something to watch out for in the full-year results will be the one-off impacts of a $29 million legal settlement, which AMP agreed to in December, and another settled for $75 million earlier in the year.

The first settlement was related to a class action brought against the company in 2020 regarding “commissions for advice and insurance advice” in the company’s own words.

The lawsuit related to the payment of commissions for the period from July 2014 to February 2021, with claims brought against AMP and some of its subsidiaries, which were previously part of the AMP advice network.

AMP Chief Executive Officer Alexis George said last month, “I’m pleased that we have resolved another legacy legal matter as we focus on the future and on delivering for our customers and members”.

The company also, earlier in the second half of the year, settled another class action in the superannuation area for $120 million, with AMP to contribute $75 million and the balance to be met by insurance.

Continuing to innovate

In the company’s most recent business update in October, AMP said its assets under management had grown 3% to $159.5 billion.

Ms George said at the time the company was continuing to innovate in areas which financial advisers value, “such as managed portfolios, where assets under management is now $23.8 billion”.

She went on to say:

In our super business, net cash flows for the quarter improved almost 28% on the same period last year, bringing us closer to achieving a sustainable positive net cash flow position. We are continuing to drive member retention by providing exclusive access for AMP members to our intuitive digital advice journeys and our innovative retirement solution, AMP Lifetime Super. In August we enhanced our proposition further when AMP Super became the first major super fund to offer cashback rewards that can boost members’ super balances – leveraging Citro’s established rewards platform.

AMP was valued at $4.58 billion at the close of trade on Wednesday.

The post Own AMP shares? Here are your key dates for the year appeared first on The Motley Fool Australia.

More reading

• AMP settles legacy class action for $29 million

Motley Fool contributor Cameron England has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.